Article
A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
Best practice & research. Clinical haematology - 1 Jun 2014
Rampal Raajit, Levine Ross L
Abstract excerpt
The discovery of the JAK2 mutation in Philadelphia-chromosome negative myeloproliferative neoplasm (MPNs) in 2005 has heralded an era of rapid genetic discovery in the MPNs. This has lead to substantive gains in the understanding of the pathobiology of these diseases. Importantly, this has also lead to new treatment in the form of JAK inhibitors, as well as to clinical trials targeting other components thought to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.